Abgenix Expands Antibody Agreements With Chiron
As in the terms of the December 1999 agreement, Abgenix will receive technology access fees, and could receive milestone and license payments, plus royalties on any future product sales by Chiron. Chiron will be responsible for product development, manufacturing, and commercialization of any products developed through the program.
"We are pleased with Chiron’s interest in adding new targets for antibody-based therapies," stated R. Scott Greer, chairman and chief executive officer of Abgenix. "We are delighted to provide extended access to XenoMouse™ technology to our existing customers."
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.